Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
giredestrant + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous
01
Overview
This is a combination therapy consisting of giredestrant (a selective estrogen receptor antagonist and degrader) plus pertuzumab and trastuzumab (HER2-targeted monoclonal antibodies). The combination is designed to simultaneously target both the estrogen receptor (ER) and HER2 pathways in breast cancer. Giredestrant blocks the cancer cell's ability to use estrogen for growth, while pertuzumab and trastuzumab attach to HER2 on cancer cells to prevent HER2-driven growth. This approach aims to overcome potential resistance mechanisms in HER2-positive, ER-positive breast cancer by addressing the bi-directional crosstalk between these pathways.
- Brand names
- Phesgo
- Other names
- giredestrant + Phesgo
02
Targets
HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)ER (Estrogen receptor)
Beyond the preview
Go deeper on giredestrant + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on giredestrant + pertuzumab + trastuzumab.